NextVivo
Private Company
Total funding raised: $4.2M
Overview
NextVivo is a private, preclinical-stage biotech leveraging a proprietary air-liquid interface (ALI) organoid platform to build holistic, human-derived tissue models that retain functional immune cells. This technology aims to overcome the limitations of traditional in vitro and animal models by providing physiologically accurate systems for drug discovery and development, particularly for cancer and immune-related diseases. The company, a spinout from Stanford University, launched with seed financing from Khosla Ventures and is positioned as a platform company with the potential to develop its own therapeutic programs.
Technology Platform
Proprietary air-liquid interface (ALI) organoid technology that grows 3D, human-derived tissue models retaining functional, diverse immune cell populations. Includes tumor microenvironment organoids and lymphoid organoids that model germinal center antibody responses.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competes with other organoid and complex in vitro model companies (e.g., Crown Bioscience, Hubrecht Organoid Technology), as well as providers of humanized mouse models. Differentiation lies in the specific claim of retaining a full, functional human immune system within 3D tissue models via the ALI method. Also competes broadly with all therapeutic companies in its disease areas.